Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease

Christian Torp-Pedersen; A John Camm; Noam N Butterfield; Garth Dickinson; Gregory N Beatch

doi:10.1016/j.ijcard.2011.10.108

Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease

Christian Torp-Pedersen, A John Camm, Noam N Butterfield, Garth Dickinson, Gregory N Beatch

27 Citationer (Scopus)

Abstract

Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

Originalsprog	Engelsk
Tidsskrift	International Journal of Cardiology
Vol/bind	166
Udgave nummer	1
Sider (fra-til)	147-51
Antal sider	5
ISSN	0167-5273
DOI	https://doi.org/10.1016/j.ijcard.2011.10.108
Status	Udgivet - 5 jun. 2013

Adgang til dokumentet

10.1016/j.ijcard.2011.10.108

Citationsformater

@article{b50ca2e2b8924487beebfec1a8c9506d,

title = "Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease",

abstract = "Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).",

author = "Christian Torp-Pedersen and Camm, {A John} and Butterfield, {Noam N} and Garth Dickinson and Beatch, {Gregory N}",

year = "2013",

month = jun,

day = "5",

doi = "10.1016/j.ijcard.2011.10.108",

language = "English",

volume = "166",

pages = "147--51",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Vernakalant

T2 - Conversion of atrial fibrillation in patients with ischemic heart disease

AU - Torp-Pedersen, Christian

AU - Camm, A John

AU - Butterfield, Noam N

AU - Dickinson, Garth

AU - Beatch, Gregory N

PY - 2013/6/5

Y1 - 2013/6/5

N2 - Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

AB - Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

U2 - 10.1016/j.ijcard.2011.10.108

DO - 10.1016/j.ijcard.2011.10.108

M3 - Journal article

C2 - 22108512

SN - 0167-5273

VL - 166

SP - 147

EP - 151

JO - International Journal of Cardiology

JF - International Journal of Cardiology

IS - 1

ER -

Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater